|Iris Pharma Expands Senior Management Team
FRANCE - March 29, 2011 - Iris Pharma, a world leader CRO specialized in ophthalmology, is pleased to announce the appointment of Philippe Margaron, Ph.D. as Head of Preclinical Department.
Dr. Margaron will manage all preclinical and research activities and provide strategic leadership to expand preclinical services capabilities to meet evolving demands from the industry. Working closely with business development, his team will offer advanced solutions and high level quality support that bring immediate value to customers' projects.
With two decades of experience in the biopharmaceutical industry, Dr. Margaron comes with an extensive experience in ophthalmic drug development and the evaluation of novel ocular therapies and drug delivery systems; he also contributed to several regulatory filings.
“As the newest member of the management team I am excited to have the opportunity to significantly contribute to growing Iris Pharma's leadership position in providing ophthalmic R&D services,” Philippe Margaron said. “What attracts me to Iris Pharma is the team's diverse, first-rate expertise in preclinical and clinical ophthalmology and capability to understand the clients' objectives and effectively provide timely answers to address their drug development needs.”
Dr Margaron joins IRIS PHARMA from Charlesson LLC, an Oklahoma-based start-up engaged in the development of innovative ophthalmics, where he served as Vice-President of Research & Development. Prior to this role, Dr Margaron spent over 15 years with QLT, Inc. a Canadian global biopharmaceutical company dedicated to ophthalmology. His most recent responsibilities included the ocular research programs. Until his appointment with Iris Pharma, Dr. Margaron was also a consultant providing strategic advice and tactical support to start-ups and established biopharmaceuticals on their preclinical programs in ophthalmology.
“We are extremely pleased that Philippe has joined the Iris Pharma team,” said Dr. Pierre-Paul Elena, Founder and CEO. “Philippe comes to Iris Pharma with deep valuable experience in product development both from an industrial and services provider point of view. His presence represents a big step forward in strengthening our operational, R&D and strategic capabilities and equiping us for our next level of growth.”
Pharma is an independent CRO that specializes in preclinical and
clinical research in the field of ophthalmology. Founded in 1989 by Dr
Pierre-Paul Elena, Iris Pharma offers its services and expertise in the
development of ophthalmic drugs and ocular medical devices to the
pharmaceutical industry and biotechnology companies around the world.
Among its clients, 8 out of the top 10 world’s largest
pharmaceuticals have chosen Iris Pharma. The company has five main
areas of activity: preclinical studies and services, clinical trials
(Phase I and IV and medico-marketing surveys), bioanalysis, preclinical
formulation, and consulting services. Iris Pharma was recently awarded
the « High Performance Prize » from the Newspaper
Les Echos in recognition of its growth performance.